Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

157 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Management of advanced ovarian cancer in Spain: an expert Delphi consensus.
Redondo A, Oaknin A, Rubio MJ, Barretina-Ginesta MP, de Juan A, Manso L, Romero I, Martin-Lorente C, Poveda A, Gonzalez-Martin A. Redondo A, et al. Among authors: oaknin a. J Ovarian Res. 2021 May 26;14(1):72. doi: 10.1186/s13048-021-00816-x. J Ovarian Res. 2021. PMID: 34039386 Free PMC article.
Feasibility of a modified outpatient regimen of intravenous/intraperitoneal chemotherapy in optimally debulked stage III ovarian cancer patients: a GEICO study.
Oaknin A, Roda D, González-Martín A, Chiva L, García-Donas J, de Juan A, Redondo A, Martínez S, García Y, Catot S, Ponce J, Del Campo JM, Cervantes A, Poveda A. Oaknin A, et al. Int J Gynecol Cancer. 2011 Aug;21(6):1048-55. doi: 10.1097/IGC.0b013e31821ee777. Int J Gynecol Cancer. 2011. PMID: 21738038 Clinical Trial.
Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer.
Gonzalez-Martin A, Gladieff L, Tholander B, Stroyakovsky D, Gore M, Scambia G, Kovalenko N, Oaknin A, Ronco JP, Freudensprung U, Pignata S; OCTAVIA Investigators. Gonzalez-Martin A, et al. Among authors: oaknin a. Eur J Cancer. 2013 Dec;49(18):3831-8. doi: 10.1016/j.ejca.2013.08.002. Epub 2013 Sep 2. Eur J Cancer. 2013. PMID: 24007819 Clinical Trial.
Updated results from OCTAVIA (front-line bevacizumab, carboplatin and weekly paclitaxel therapy for ovarian cancer).
Gonzalez-Martin A, Gladieff L, Tholander B, Stroyakovsky D, Gore M, Scambia G, Oaknin A, Sneller V, Freudensprung U, Pignata S; OCTAVIA Investigators. Gonzalez-Martin A, et al. Among authors: oaknin a. Eur J Cancer. 2014 Mar;50(4):862-3. doi: 10.1016/j.ejca.2013.12.001. Epub 2014 Jan 10. Eur J Cancer. 2014. PMID: 24418723 No abstract available.
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I. Pujade-Lauraine E, et al. Among authors: oaknin a. J Clin Oncol. 2014 May 1;32(13):1302-8. doi: 10.1200/JCO.2013.51.4489. Epub 2014 Mar 17. J Clin Oncol. 2014. PMID: 24637997 Clinical Trial.
Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial.
Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher DM, Karlan BY, Lhommé C, Richardson G, Rincón DG, Coleman RL, Herzog TJ, Marth C, Brize A, Fabbro M, Redondo A, Bamias A, Tassoudji M, Navale L, Warner DJ, Oza AM. Monk BJ, et al. Among authors: oaknin a. Lancet Oncol. 2014 Jul;15(8):799-808. doi: 10.1016/S1470-2045(14)70244-X. Epub 2014 Jun 17. Lancet Oncol. 2014. PMID: 24950985 Clinical Trial.
Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2.
Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher DM, Karlan BY, Lhommé C, Richardson G, Rincón DG, Coleman RL, Marth C, Brize A, Fabbro M, Redondo A, Bamias A, Ma H, Vogl FD, Bach BA, Oza AM. Monk BJ, et al. Among authors: oaknin a. Gynecol Oncol. 2016 Oct;143(1):27-34. doi: 10.1016/j.ygyno.2016.07.112. Epub 2016 Aug 18. Gynecol Oncol. 2016. PMID: 27546885 Clinical Trial.
[Recommendations for biomarker testing in epithelial ovarian cancer. A national consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology].
Oaknin A, Guarch R, Barretina P, Hardisson D, González-Martín A, Matías-Guiu X, Pérez-Fidalgo A, Vieites B, Romero I, Palacios J. Oaknin A, et al. Rev Esp Patol. 2018 Apr-Jun;51(2):84-96. doi: 10.1016/j.patol.2017.11.002. Epub 2018 Jan 17. Rev Esp Patol. 2018. PMID: 29602379 Spanish.
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P. Moore K, et al. Among authors: oaknin a. N Engl J Med. 2018 Dec 27;379(26):2495-2505. doi: 10.1056/NEJMoa1810858. Epub 2018 Oct 21. N Engl J Med. 2018. PMID: 30345884 Clinical Trial.
Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial.
DiSilvestro P, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian CA, Bradley WH, Mathews CA, Liu J, Lowe ES, Bloomfield R, Moore KN. DiSilvestro P, et al. Among authors: oaknin a. J Clin Oncol. 2020 Oct 20;38(30):3528-3537. doi: 10.1200/JCO.20.00799. Epub 2020 Aug 4. J Clin Oncol. 2020. PMID: 32749942 Free PMC article.
157 results